Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States.

It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis.

The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions.

Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.